Literature DB >> 35633420

Five-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort.

Lu Kong1,2,3, Xiu-Jian Ma4, Xiao-Ying Xu2,3, Pan-Pan Liu2,3, Ze-Yu Wu2,3, Li-Wei Zhang2,3, Jun-Ting Zhang2,3, Zhen Wu2,3, Liang Wang5,6, Da Li7,8.   

Abstract

Hemorrhage of brainstem cavernous malformation (CM) would cause various symptoms and severe disability. The study aimed to elaborate on the 5-year actuarial cumulative hazard of symptomatic hemorrhage. Patients diagnosed in our institute between 2009 and 2013 were prospectively registered. All clinical data were obtained, follow-up was performed, and risk factors were evaluated. Four hundred sixty-eight patients (217 female, 46.4%) were included in the study with a median follow-up duration of 79.0 months. A total of 137 prospective hemorrhages occurred in 107 patients (22.9%) during 1854.0 patient-years. Multivariate Cox analysis found age ≥ 55 years (hazard ratio (HR) 2.166, p = 0.002), DVA (HR 1.576, p = 0.026), superficial-seated location (HR 1.530, p = 0.047), and hemorrhage on admission (HR 2.419, p = 0.026) as independent risk factors for hemorrhage. The 5-year cumulative hazard of hemorrhage was 30.8% for the overall cohort, 47.8% for 60 patients with age ≥ 55 years, 43.7% for 146 patients with DVA, 37.9% for 272 patients with superficial-seated lesions, and 37.2% for 341 patients with hemorrhage on admission. As a stratified analysis, within subcohort of 341 patients with a hemorrhagic presentation, age ≥ 55 years (HR 3.005, p < 0.001), DVA (HR 1.801, p = 0.010), and superficial-seated location (HR 2.276, p = 0.001) remained independently significant. The 5-year cumulative hazard of hemorrhage was 52.0% for 119 patients with both DVA and hemorrhagic presentation. The 5-year cumulative hemorrhagic risk was 30.8% and was higher in subgroups if harboring risk factors that helped to predict potential hemorrhagic candidates and were useful for treatment decision-making.Clinical Trial Registration-URL: http://www.chictr.org.cn Unique identifier: ChiCTR-POC-17011575.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Brainstem cavernous malformation; Cavernoma; Cerebral cavernous malformation; Hemorrhage risk; Natural history

Mesh:

Year:  2022        PMID: 35633420     DOI: 10.1007/s10143-022-01815-2

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   2.800


  24 in total

1.  Prospective hemorrhage risk of intracerebral cavernous malformations.

Authors:  K D Flemming; M J Link; T J H Christianson; R D Brown
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

2.  The natural history of cerebral cavernous malformations in children.

Authors:  Bradley A Gross; Rose Du; Darren B Orbach; R Michael Scott; Edward R Smith
Journal:  J Neurosurg Pediatr       Date:  2015-10-16       Impact factor: 2.375

3.  Hemorrhage from cerebral cavernous malformations: a systematic pooled analysis.

Authors:  Bradley A Gross; Rose Du
Journal:  J Neurosurg       Date:  2016-05-20       Impact factor: 5.115

Review 4.  Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory Board.

Authors:  Rustam Al-Shahi Salman; Michel J Berg; Leslie Morrison; Issam A Awad
Journal:  Stroke       Date:  2008-10-30       Impact factor: 7.914

5.  Hemorrhage from cerebral cavernous malformations: The role of associated developmental venous anomalies.

Authors:  Bixia Chen; Annika Herten; Dino Saban; Steffen Rauscher; Alexander Radbruch; Boerge Schmidt; Yuan Zhu; Ramazan Jabbarli; Karsten H Wrede; Christoph Kleinschnitz; Ulrich Sure; Philipp Dammann
Journal:  Neurology       Date:  2020-06-08       Impact factor: 9.910

6.  Top ten research priorities for brain and spine cavernous malformations.

Authors:  Rustam Al-Shahi Salman; Neil Kitchen; Jennifer Thomson; Vijeya Ganesan; Conor Mallucci; Matthias Radatz
Journal:  Lancet Neurol       Date:  2016-01-30       Impact factor: 44.182

7.  Modifiable Cardiovascular Risk Factors in Patients With Sporadic Cerebral Cavernous Malformations: Obesity Matters.

Authors:  Bixia Chen; Dino Saban; Steffen Rauscher; Annika Herten; Laurèl Rauschenbach; Alejandro Santos; Yan Li; Boerge Schmidt; Yuan Zhu; Ramazan Jabbarli; Karsten H Wrede; Christoph Kleinschnitz; Ulrich Sure; Philipp Dammann
Journal:  Stroke       Date:  2021-02-16       Impact factor: 7.914

8.  Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study.

Authors:  Rustam Al-Shahi Salman; Julie M Hall; Margaret A Horne; Fiona Moultrie; Colin B Josephson; Jo J Bhattacharya; Carl E Counsell; Gordon D Murray; Vakis Papanastassiou; Vaughn Ritchie; Richard C Roberts; Robin J Sellar; Charles P Warlow
Journal:  Lancet Neurol       Date:  2012-01-31       Impact factor: 44.182

9.  Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data.

Authors:  Margaret A Horne; Kelly D Flemming; I-Chang Su; Christian Stapf; Jin Pyeong Jeon; Da Li; Susanne S Maxwell; Philip White; Teresa J Christianson; Ronit Agid; Won-Sang Cho; Chang Wan Oh; Zhen Wu; Jun-Ting Zhang; Jeong Eun Kim; Karel Ter Brugge; Robert Willinsky; Robert D Brown; Gordon D Murray; Rustam Al-Shahi Salman
Journal:  Lancet Neurol       Date:  2015-12-02       Impact factor: 44.182

Review 10.  Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel.

Authors:  Amy Akers; Rustam Al-Shahi Salman; Issam A Awad; Kristen Dahlem; Kelly Flemming; Blaine Hart; Helen Kim; Ignacio Jusue-Torres; Douglas Kondziolka; Cornelia Lee; Leslie Morrison; Daniele Rigamonti; Tania Rebeiz; Elisabeth Tournier-Lasserve; Darrel Waggoner; Kevin Whitehead
Journal:  Neurosurgery       Date:  2017-05-01       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.